WO2012027473A3 - Compositions immunogènes comprenant des antigènes de la protéine e du virus de la dengue à vecteurs d'alphavirus - Google Patents
Compositions immunogènes comprenant des antigènes de la protéine e du virus de la dengue à vecteurs d'alphavirus Download PDFInfo
- Publication number
- WO2012027473A3 WO2012027473A3 PCT/US2011/048971 US2011048971W WO2012027473A3 WO 2012027473 A3 WO2012027473 A3 WO 2012027473A3 US 2011048971 W US2011048971 W US 2011048971W WO 2012027473 A3 WO2012027473 A3 WO 2012027473A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dengue virus
- alphavirus
- vectored
- immunogenic compositions
- protein antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Cette invention concerne un vecteur d'alphavirus comprenant un antigène de la protéine E du virus de la dengue. Cette invention concerne également des acides nucléiques codant ou comprenant ce vecteur. L'invention concerne également des compositions multivalentes et des préparations pharmaceutiques comprenant au moins deux vecteurs d'alphavirus ou acides nucléiques selon l'invention. L'invention concerne par ailleurs des méthodes d'administration de ces vecteurs d'alphavirus, de ces acides nucléiques, de ces compositions et/ou de ces préparations pharmaceutiques chez un sujet, notamment pour induire une réponse immunitaire dirigée contre le virus de la dengue, pour traiter l'infection par le virus de la dengue, pour prévenir l'infection par le virus de la dengue et/ou pour protéger un sujet des effets d'une infection par le virus de la dengue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37663010P | 2010-08-24 | 2010-08-24 | |
US61/376,630 | 2010-08-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012027473A2 WO2012027473A2 (fr) | 2012-03-01 |
WO2012027473A3 true WO2012027473A3 (fr) | 2012-08-16 |
Family
ID=45724045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/048971 WO2012027473A2 (fr) | 2010-08-24 | 2011-08-24 | Compositions immunogènes comprenant des antigènes de la protéine e du virus de la dengue à vecteurs d'alphavirus |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012027473A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014210358A1 (fr) | 2013-06-26 | 2014-12-31 | The University Of North Carolina At Chapel Hill | Procédés et compositions pour des vaccins contre le virus de la dengue |
CN113736750B (zh) * | 2021-09-22 | 2023-03-31 | 中牧实业股份有限公司 | 一株盖他病毒毒株及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165477A (en) * | 1995-05-24 | 2000-12-26 | Hawaii Biotechnology Group, Inc. | Subunit immonogenic composition against dengue infection |
US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
US20040009469A1 (en) * | 2002-02-26 | 2004-01-15 | Maxygen, Inc. Patent Department | Novel flavivirus antigens |
US20090155301A1 (en) * | 2006-02-27 | 2009-06-18 | Mason Peter W | Pseudoinfectious flavivirus and uses thereof |
-
2011
- 2011-08-24 WO PCT/US2011/048971 patent/WO2012027473A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165477A (en) * | 1995-05-24 | 2000-12-26 | Hawaii Biotechnology Group, Inc. | Subunit immonogenic composition against dengue infection |
US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
US20040009469A1 (en) * | 2002-02-26 | 2004-01-15 | Maxygen, Inc. Patent Department | Novel flavivirus antigens |
US20090155301A1 (en) * | 2006-02-27 | 2009-06-18 | Mason Peter W | Pseudoinfectious flavivirus and uses thereof |
Non-Patent Citations (1)
Title |
---|
LAURA J. WHITE ET AL.: "An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice.", JOURNAL OF VIROLOGY., vol. 81, no. 19, 2007, pages 10329 - 10339 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012027473A2 (fr) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006113214A3 (fr) | Vaccin contre des souches pandemiques des virus de la grippe | |
EP4104854A3 (fr) | Vaccins multivalents pour le virus de la rage et les coronavirus | |
WO2010037027A3 (fr) | Immunisation d'oiseaux par administration mucosale de vaccins portés sur vecteur et incapables de se répliquer | |
WO2007095318A3 (fr) | antigenes de la grippe, compositions de vaccins et procedes associes | |
WO2012106377A3 (fr) | Molécules d'acide nucléique codant de nouveaux antigènes d'herpès, vaccin les comprenant et procédés pour les utiliser | |
WO2015044292A8 (fr) | Compositions de thérapie génique destinées à être utilisées dans la prévention et/ou le traitement d'une stéatose hépatique non-alcoolique | |
WO2007022151A3 (fr) | Immunisation d'oiseaux par administration de vaccins a vecteurs non repliquants | |
WO2009026397A3 (fr) | Vaccins antigrippaux prophylactiques et thérapeutiques, antigènes, compositions et procédés | |
WO2006078294A3 (fr) | Vecteurs d'alphavirus pour vaccins contre pathogenes respiratoires | |
WO2007092792A3 (fr) | Vaccin à base de levure destiné à induire une réponse immunitaire | |
WO2014018858A3 (fr) | Vaccin à protéine de fusion multimérique et produit immunothérapeutique | |
DK2707393T3 (da) | Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a | |
WO2013106834A3 (fr) | Peptides wt-1 immunogènes et leurs procédés d'utilisation | |
WO2010019262A3 (fr) | Vaccin polyvalent | |
EA201290675A1 (ru) | Вакцинные векторы и способы усиления иммунных ответов | |
WO2012021730A3 (fr) | Vaccin contre le virus syncytial respiratoire (vsr) | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
WO2008134643A3 (fr) | Antigènes de trypanosome, compositions de vaccins et procédés associés | |
WO2012047679A3 (fr) | Produits de synthèse d'antigène consensus et vaccins fabriqués à partir de ceux-ci, et procédés d'utilisation de ceux-ci pour traiter le paludisme | |
WO2017214596A8 (fr) | Compositions et procédés pour prévenir et traiter l'infection par le virus zika | |
WO2008054535A3 (fr) | Nouveaux vaccins contre l'influenza m2 | |
WO2009080715A3 (fr) | Vaccins anti-malaria | |
WO2011159814A3 (fr) | Nouveaux vaccins de rappel recombinants vivants | |
WO2008115314A3 (fr) | Vecteur vaccinal flavivirus contre le virus de la grippe | |
MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11820596 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11820596 Country of ref document: EP Kind code of ref document: A2 |